Reactive Infectious Mucocutaneous Eruption Associated With SARS-CoV-2 Infection | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Views 13,855
Citations 0
April 7, 2021

Reactive Infectious Mucocutaneous Eruption Associated With SARS-CoV-2 Infection

Author Affiliations
  • 1Harvard Combined Dermatology Residency Program, Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
  • 2Dermatology Program, Boston Children's Hospital, Boston, Massachusetts
JAMA Dermatol. Published online April 7, 2021. doi:10.1001/jamadermatol.2021.0385

As COVID-19, caused by SARS-CoV-2, spreads worldwide, various patterns of associated dermatologic diseases continue to emerge. Early reports classified multiple cutaneous manifestations of SARS-CoV-2 infection.1 In this article, we report the observation of a newly associated mucocutaneous eruption in a pediatric patient with confirmed SARS-CoV-2 infection.

A previously healthy 17-year-old male presented to the emergency department with 3 days of mouth pain and nonpainful penile erosions. One week prior, he experienced transient anosmia and ageusia that had since spontaneously resolved. At that time, he was tested for SARS-CoV-2 infection via nasopharyngeal polymerase chain reaction (PCR), the results of which were positive. He denied fever, cough, dyspnea, rhinorrhea, and gastrointestinal symptoms at any time. Although he had taken acetaminophen and ibuprofen before presenting to the emergency department, he took no medications before the onset of his mucocutaneous eruption.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words